FDA Prescription Drug User Fee Program Will Get OIG Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to user fees, upcoming FDA reviews will also focus on oversight of post-marketing requirements and information exchange in the drug supply chain.
You may also be interested in...
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
FDA tells industry that proposal on trials also can’t use SPA-like process.
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.
Biosimilar Substitution In Medicare Part D Formularies Mid-Year Established In Final Rule
Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.